

Henry M Prince

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2422332/publications.pdf>

Version: 2024-02-01

215
papers

12,821
citations

38742

50
h-index

25787

108
g-index

216
all docs

216
docs citations

216
times ranked

11513
citing authors

#	ARTICLE	IF	CITATIONS
1	Alcohol and tobacco use and risk of multiple myeloma: A case-control study. <i>EJHaem</i> , 2022, 3, 109-120.	1.0	3
2	Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. <i>Blood</i> , 2022, 140, 419-437.	1.4	58
3	Cost-Effectiveness of Extracorporeal Photopheresis for the Treatment of Patients With Erythrodermic (Stage T4, M0) Cutaneous T-Cell Lymphoma in the Australian Setting. <i>Value in Health</i> , 2022, 25, 965-974.	0.3	3
4	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. <i>Lancet Oncology</i> , 2022, 23, 416-427.	10.7	54
5	Epigenetic Modifications in Lymphoma and Their Role in the Classification of Lymphomas. <i>Hemato</i> , 2022, 3, 174-187.	0.6	0
6	Associations between Smoking and Alcohol and Follicular Lymphoma Incidence and Survival: A Family-Based Case-Control Study in Australia. <i>Cancers</i> , 2022, 14, 2710.	3.7	4
7	Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM): Interim phase 1b study results.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8025-8025.	1.6	4
8	The importance of differentiating between mycosis fungoides with CD30-positive large cell transformation and mycosis fungoides with coexistent primary cutaneous anaplastic large cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 185-187.	1.2	7
9	Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*. <i>British Journal of Dermatology</i> , 2021, 184, 722-730.	1.5	39
10	Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study*. <i>British Journal of Dermatology</i> , 2021, 184, 524-531.	1.5	18
11	Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2021, 62, 330-336.	1.3	5
12	Efficacy and safety of weekly carfilzomib (70 mg/m ²), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. <i>Leukemia and Lymphoma</i> , 2021, 62, 358-367.	1.3	13
13	Allogeneic haematopoietic stem cell transplantation for advanced stage mycosis fungoides and Sézary syndrome: never-late, never-never?. <i>Bone Marrow Transplantation</i> , 2021, 56, 1232-1234.	2.4	2
14	Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs. <i>Frontiers in Immunology</i> , 2021, 12, 632399.	4.8	30
15	Targeted Approaches to T-Cell Lymphoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 481.	2.5	1
16	Management of hydroxyurea resistant or intolerant polycythemia vera. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-10.	1.3	4
17	Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. <i>European Journal of Cancer</i> , 2021, 148, 411-421.	2.8	27
18	An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma. <i>Expert Review of Hematology</i> , 2021, 14, 419-427.	2.2	0

#	ARTICLE	IF	CITATIONS
19	Myeloma natural killer cells are exhausted and have impaired regulation of activation. <i>Haematologica</i> , 2021, 106, 2522-2526.	3.5	8
20	<scp>COVID</scp>â€19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. <i>Internal Medicine Journal</i> , 2021, 51, 763-768.	0.8	12
21	Advances in Frontline Management of Peripheral T-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 368-378.	0.4	0
22	A cautionary tale of the use of lenalidomide and dexamethasone for relapsed/refractory immunoglobulin light chain (AL) amyloidosis. <i>British Journal of Haematology</i> , 2021, 195, 160-161.	2.5	2
23	An Update on the Current Genomic Landscape of Breast Implant-Associated Anaplastic Large Cell Lymphoma. <i>Cancers</i> , 2021, 13, 4921.	3.7	1
24	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physicianâ€™s choice in cutaneous T-cell lymphoma: final data. <i>Blood Advances</i> , 2021, 5, 5098-5106.	5.2	46
25	Successful identification of predictive profiles for infection utilising systemsâ€level immune analysis: a pilot study in patients with relapsed and refractory multiple myeloma. <i>Clinical and Translational Immunology</i> , 2021, 10, e1235.	3.8	3
26	Treatment efficacy for SÃ©zary syndrome: an international, multi-centre, comparative study of current systemic therapies. <i>European Journal of Cancer</i> , 2021, 156, S20.	2.8	0
27	Gram-Negative Bacterial Lipopolysaccharide Promotes Tumor Cell Proliferation in Breast Implant-Associated Anaplastic Large-Cell Lymphoma. <i>Cancers</i> , 2021, 13, 5298.	3.7	8
28	Mycosis fungoides and SÃ©zary syndrome: Australian clinical practice statement. <i>Australasian Journal of Dermatology</i> , 2021, 62, e8-e18.	0.7	4
29	A feasibility and acceptability study of an adaptation of the Mindful Self-Compassion program for adult cancer patients. <i>Palliative and Supportive Care</i> , 2020, 18, 130-140.	1.0	20
30	Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia: A Longitudinal Study of Implant and Other Related Risk Factors. <i>Aesthetic Surgery Journal</i> , 2020, 40, 838-846.	1.6	36
31	A practical guide to laboratory investigations at diagnosis and follow up in WaldenstrÃ¶m macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. <i>Pathology</i> , 2020, 52, 167-178.	0.6	23
32	Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 2153.	4.8	16
33	Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. <i>Blood Advances</i> , 2020, 4, 4802-4811.	5.2	33
34	Pralatrexate and angioimmunoblastic T-cell lymphoma: time for a second look?. <i>Leukemia and Lymphoma</i> , 2020, 61, 2031-2033.	1.3	0
35	Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma. <i>Cancers</i> , 2020, 12, 3125.	3.7	6
36	Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma. <i>Cancers</i> , 2020, 12, 2311.	3.7	38

#	ARTICLE	IF	CITATIONS
37	Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. <i>Blood Cancer Journal</i> , 2020, 10, 111.	6.2	13
38	Primary cutaneous anaplastic large cell lymphoma and evolving clinical practice: 26 years of skin lesions with locoregional progression to systemic disease. <i>Leukemia and Lymphoma</i> , 2020, 61, 2268-2270.	1.3	0
39	Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. <i>European Journal of Cancer</i> , 2020, 133, 120-130.	2.8	21
40	Durable Complete Remission and Long-Term Survival in FDG-PET Staged Patients with Stage III Follicular Lymphoma, Treated with Wide-Field Radiation Therapy. <i>Cancers</i> , 2020, 12, 991.	3.7	0
41	T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4640-4647.	5.2	50
42	Etiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Current Directions in Research. <i>Cancers</i> , 2020, 12, 3861.	3.7	26
43	Psoriasis and cancer. An Australian/New Zealand narrative. <i>Australasian Journal of Dermatology</i> , 2019, 60, 12-18.	0.7	21
44	The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment. <i>Cancers</i> , 2019, 11, 928.	3.7	5
45	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet</i> , 2019, 394, 2096-2107.	13.7	435
46	A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG) Tj ETQq0 0.0.8BT /Overlock 10 T	0.8	0
47	Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study. <i>Leukemia and Lymphoma</i> , 2019, 60, 2122-2133.	1.3	12
48	Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with SÅ©zary syndrome. <i>Blood</i> , 2019, 134, 1346-1350.	1.4	29
49	Lack of Durable Remission with Conventional-Dose Total Skin Electron Therapy for the Management of Sezary Syndrome and Multiply Relapsed Mycosis Fungoides. <i>Cancers</i> , 2019, 11, 1758.	3.7	5
50	Statin-induced anti-HMCCR antibody-related immune-mediated necrotising myositis achieving complete remission with rituximab. <i>BMJ Case Reports</i> , 2019, 12, e232406.	0.5	10
51	A Novel Application of [18F]Fluorothymidine-PET ([18F]FLT-PET) in Clinical Practice to Quantify Regional Bone Marrow Function in a Patient With Treatment-Induced Cytopenias and to Guide ÅœMarrow-SparingÅœ Radiotherapy. <i>Clinical Nuclear Medicine</i> , 2019, 44, e624-e626.	1.3	6
52	Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2Å Mutation or Concurrent MDS. <i>HemaSphere</i> , 2019, 3, e187.	2.7	14
53	The Epidemiology of Breast ImplantÅ Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand Confirms the Highest Risk for Grade 4 Surface Breast Implants. <i>Plastic and Reconstructive Surgery</i> , 2019, 143, 1285-1292.	1.4	114
54	Molecular Drivers of Breast ImplantÅ Associated Anaplastic Large Cell Lymphoma. <i>Plastic and Reconstructive Surgery</i> , 2019, 143, 59S-64S.	1.4	28

#	ARTICLE	IF	CITATIONS
55	A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 904-911.	1.3	8
56	FDG-PET/CT findings, the vital clue to rare diagnosis of herpes simplex virus lymphadenitis simulating Richter transformation. <i>Pathology</i> , 2019, 51, 102-104.	0.6	1
57	Brentuximab vedotin in T-cell lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 5-19.	2.2	18
58	Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma. <i>Scientific Reports</i> , 2018, 8, 4159.	3.3	79
59	Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. <i>Internal Medicine Journal</i> , 2018, 48, 210-220.	0.8	31
60	Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and S�azary Syndrome. <i>Current Oncology Reports</i> , 2018, 20, 32.	4.0	31
61	Brentuximab vedotin: targeting CD30 as standard in CTCL. <i>Oncotarget</i> , 2018, 9, 11887-11888.	1.8	5
62	Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. <i>Haematologica</i> , 2018, 103, 2088-2096.	3.5	187
63	Breast Implant-Associated Anaplastic Large Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 516-524.	2.3	34
64	A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy. <i>Current Rheumatology Reports</i> , 2018, 20, 64.	4.7	6
65	IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 691-697.	4.1	12
66	Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1758.	4.1	19
67	Integrating novel systemic therapies for the treatment of mycosis fungoides and S�azary syndrome. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 322-335.	1.7	8
68	Germline TIM-3 Mutations Characterize Sub-Cutaneous Panniculitis T-Cell Lymphomas with Hemophagocytic Lymphohistiocytic Syndrome. <i>Blood</i> , 2018, 132, 1569-1569.	1.4	0
69	Central nervous system immune reconstitution inflammatory syndrome after ibrutinib therapy for Richter transformation. <i>Leukemia and Lymphoma</i> , 2017, 58, 207-210.	1.3	4
70	Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. <i>British Journal of Haematology</i> , 2017, 177, 441-448.	2.5	21
71	Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. <i>Leukemia and Lymphoma</i> , 2017, 58, 2335-2341.	1.3	13
72	Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased Risk. <i>Plastic and Reconstructive Surgery</i> , 2017, 140, 645-654.	1.4	295

#	ARTICLE	IF	CITATIONS
73	Trends in the surgical management of stage 1 renal cell carcinoma: findings from a population-based study. <i>BJU International</i> , 2017, 120, 6-14.	2.5	19
74	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet, The</i> , 2017, 390, 555-566.	13.7	444
75	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. <i>Clinical Cancer Research</i> , 2017, 23, 2478-2490.	7.0	95
76	Primary Breast Lymphoma—Population-Level Insights into an Infrequent but Increasingly Recognized Subtype of Lymphoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	5
77	Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 914-917.	1.7	50
78	Update and new approaches in the treatment of Castleman disease. <i>Journal of Blood Medicine</i> , 2016, Volume 7, 145-158.	1.7	79
79	Mycosis fungoides and Sezary syndrome: Current challenges in assessment, management and prognostic markers. <i>Australasian Journal of Dermatology</i> , 2016, 57, 182-191.	0.7	18
80	How do tumor cells respond to HDAC inhibition?. <i>FEBS Journal</i> , 2016, 283, 4032-4046.	4.7	97
81	How I treat mycosis fungoides and Sezary syndrome. <i>Blood</i> , 2016, 127, 3142-3153.	1.4	138
82	Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma. <i>Haematologica</i> , 2016, 101, e387-e390.	3.5	124
83	Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. <i>Journal of Hematology and Oncology</i> , 2016, 9, 22.	17.0	38
84	Bacterial Biofilm Infection Detected in Breast Implant-Associated Anaplastic Large-Cell Lymphoma. <i>Plastic and Reconstructive Surgery</i> , 2016, 137, 1659-1669.	1.4	286
85	High-dose thiotepa-based conditioning regimens for relapsed lymphoma involving the central nervous system: from orphan drug to a standard-of-care?. <i>Leukemia and Lymphoma</i> , 2016, 57, 1-3.	1.3	15
86	Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy. <i>Leukemia and Lymphoma</i> , 2016, 57, 1044-1053.	1.3	5
87	Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study. <i>Blood</i> , 2016, 128, 182-182.	1.4	12
88	Use of romidepsin for the treatment of mycosis fungoides and Sezary syndrome—role of romidepsin in the current therapeutic landscape and implications for future practice. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1231-1239.	0.8	1
89	Comment on "Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma". <i>Haematologica</i> , 2015, 100, e379-e379.	3.5	4
90	Cutaneous CD30 positive lymphoproliferative disorders with coexistent epithelial neoplasms: Report of two cases. <i>Australasian Journal of Dermatology</i> , 2015, 56, e83-e87.	0.7	5

#	ARTICLE	IF	CITATIONS
91	Romidepsin in peripheral and cutaneous Tâ€cell lymphoma: mechanistic implications from clinical and correlative data. <i>British Journal of Haematology</i> , 2015, 170, 96-109.	2.5	51
92	The efficacy of methotrexate for lymphomatoid papulosis. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 1088-1090.	1.2	26
93	The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit. <i>American Journal of Hematology</i> , 2015, 90, E86-91.	4.1	7
94	CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells. <i>Cancer Immunology Research</i> , 2015, 3, 483-494.	3.4	103
95	Lack of durable disease control with chemotherapy for mycosis fungoides and SÃ©zary syndrome: a comparative study of systemic therapy. <i>Blood</i> , 2015, 125, 71-81.	1.4	181
96	Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib. <i>Oncolmmunology</i> , 2015, 4, e1038011.	4.6	4
97	Prevention of thromboembolism in myeloma: expanding the tool-box of assays to predict the risk?. <i>Leukemia and Lymphoma</i> , 2015, 56, 3246-3247.	1.3	0
98	CD30 As a Target for the Treatment of Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3691-3696.	1.6	8
99	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and SÃ©zary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. <i>Journal of Clinical Oncology</i> , 2015, 33, 3766-3773.	1.6	328
100	CAR-T cells are serial killers. <i>Oncolmmunology</i> , 2015, 4, e1053684.	4.6	14
101	Emerging drugs for T-cell lymphoma. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 201-213.	2.4	4
102	Are we close to a prognostic index for cutaneous T cell lymphoma?. <i>Leukemia and Lymphoma</i> , 2014, 55, 7-8.	1.3	3
103	Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 625-634.	0.8	3
104	Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study. <i>Lancet Haematology</i> , 2014, 1, e112-e119.	4.6	8
105	Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2014, 55, 1053-1060.	1.3	12
106	Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. <i>Biomarker Research</i> , 2014, 2, 16.	6.8	26
107	Breast Implantâ€Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients. <i>Journal of Clinical Oncology</i> , 2014, 32, 114-120.	1.6	338
108	Low Uptake of Upfront Autologous Transplantation for Myeloma in a Jurisdiction With Universal Health Care Coverage: A Population-Based Patterns of Care Study in Australia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 61-67.	0.4	5

#	ARTICLE	IF	CITATIONS
109	Identifying mutant pathways in the histiocytoses. <i>Blood</i> , 2014, 124, 2901-2903.	1.4	5
110	Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Systematic Review of the Literature and Mini-Meta Analysis. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 196-210.	2.3	66
111	Duration of Response in Cutaneous T-Cell Lymphoma Patients Treated With Denileukin Diftitox: Results From 3 Phase III Studies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 377-384.	0.4	35
112	Romidepsin for peripheral T-cell lymphoma. <i>Expert Review of Hematology</i> , 2013, 6, 351-359.	2.2	9
113	Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and SÅ©zary syndrome. <i>Leukemia and Lymphoma</i> , 2013, 54, 69-75.	1.3	22
114	Panobinostat activity in both bexarotene-exposed and -naÃve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial. <i>European Journal of Cancer</i> , 2013, 49, 386-394.	2.8	124
115	Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia. <i>Molecular Therapy</i> , 2013, 21, 2122-2129.	8.2	361
116	Romidepsin for cutaneous T-cell lymphoma. <i>Future Oncology</i> , 2013, 9, 1819-1827.	2.4	19
117	Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 514-519.	1.3	13
118	Panobinostat in lymphoid and myeloid malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1211-1223.	4.1	39
119	Current Epigenetic Therapy for T-Cell Lymphoma. , 2013, , 279-296.		2
120	CD57+ NK CELLS ARE Increased In Patients With Multiple Myeloma and ARE Primed Effectors For ADCC, But NOT Natural Cytotoxicity. <i>Blood</i> , 2013, 122, 1904-1904.	1.4	8
121	Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2013, 122, 4353-4353.	1.4	4
122	Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study. <i>Blood</i> , 2013, 122, 537-537.	1.4	5
123	Histone Deacetylase Inhibitors (HDACi) Suppress Toll-Like Receptor-Induced Dendritic Cell Maturation and Alter Secretion But Not Gene Expression Of Polarising Cytokines By Dendritic Cells. <i>Blood</i> , 2013, 122, 3495-3495.	1.4	0
124	Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 631-636.	1.6	571
125	Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2197-2203.	1.6	251
126	Romidepsin for Cutaneous T-cell Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 3509-3515.	7.0	77

#	ARTICLE	IF	CITATIONS
127	Erdheim-Chester Disease Harboring the BRAF V600E Mutation. <i>Journal of Clinical Oncology</i> , 2012, 30, e331-e332.	1.6	46
128	Anaplastic Large Cell Lymphoma and Breast Implants. <i>Plastic and Reconstructive Surgery</i> , 2012, 129, 610e-617e.	1.4	58
129	Pioneering studies of histone deacetylase inhibitors in myeloma: signals of activity set the stage for combination therapy trials. <i>Leukemia and Lymphoma</i> , 2012, 53, 1658-1659.	1.3	1
130	Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sézary syndrome receiving placebo. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 867-875.	1.2	18
131	A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax®). <i>Epigenomics</i> , 2012, 4, 571-589.	2.1	39
132	The use of methotrexate in dermatology: a review. <i>Australasian Journal of Dermatology</i> , 2012, 53, 1-18.	0.7	84
133	Fludarabine and a histone deacetylase inhibitor – Strange bedfellows. <i>Leukemia Research</i> , 2012, 36, 385-386.	0.8	0
134	Managing multiple myeloma in the elderly: are we making progress?. <i>Expert Review of Hematology</i> , 2011, 4, 301-315.	2.2	6
135	Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. <i>Blood</i> , 2011, 117, 3658-3668.	1.4	128
136	A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. <i>Blood</i> , 2011, 118, 6274-6283.	1.4	83
137	Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. <i>Blood</i> , 2011, 117, 5827-5834.	1.4	428
138	EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*. <i>Blood</i> , 2011, 118, 4024-4035.	1.4	365
139	Response: dexamethasone dose alters expression of NK activating receptors in vivo. <i>Blood</i> , 2011, 118, 6466-6468.	1.4	4
140	MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi). <i>Annals of Hematology</i> , 2011, 90, 847-849.	1.8	13
141	Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: Establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity. <i>Cancer</i> , 2011, 117, 1478-1489.	4.1	66
142	New drug therapies in peripheral T-cell lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 457-472.	2.4	28
143	Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2598-2607.	1.6	550
144	Low Dose Lenalidomide and Dexamethasone Induction Followed by Autologous Transplantation In Untreated Patients with Myeloma Is Associated with High Response Rates and Preservation of CD8, but Not CD4 or NK Cellular Immunity. <i>Blood</i> , 2011, 118, 1862-1862.	1.4	9

#	ARTICLE	IF	CITATIONS
145	Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2011, 118, 591-591.	1.4	1
146	Effusion-associated anaplastic large cell lymphoma of the breast: time for it to be defined as a distinct clinico-pathological entity. <i>Haematologica</i> , 2010, 95, 1977-1979.	3.5	78
147	Development of Kaposi's sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient. <i>International Journal of Hematology</i> , 2010, 91, 347-348.	1.6	22
148	Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. <i>Investigational New Drugs</i> , 2010, 28, 3-20.	2.6	123
149	The deacetylase inhibitors "here to stay!". <i>Investigational New Drugs</i> , 2010, 28, 1-2.	2.6	42
150	Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. <i>Pharmaceuticals</i> , 2010, 3, 2674-2688.	3.8	7
151	A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. <i>Journal of Hepatology</i> , 2010, 53, 599-607.	3.7	57
152	Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1870-1877.	1.6	212
153	Lower-Dose Lenalidomide and Dexamethasone Reduces Toxicity without Compromising Efficacy In Patients with Relapsed/Refractory Myeloma, Who Are Aged ≥ 60 Years or Have Renal Impairment: Planned Interim Results of a Prospective Multicentre Phase II Trial. <i>Blood</i> , 2010, 116, 1961-1961.	1.4	10
154	TP53 Mutations In Relapsed/Refractory Multiple Myeloma (MM) Treated with Thalidomide (Thal) or Thalidomide Combination Therapy. <i>Blood</i> , 2010, 116, 4046-4046.	1.4	0
155	Clinical Studies of Histone Deacetylase Inhibitors. <i>Clinical Cancer Research</i> , 2009, 15, 3958-3969.	7.0	334
156	Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. <i>Future Oncology</i> , 2009, 5, 601-612.	2.4	119
157	IgA nephropathy associated with cutaneous T cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 2083-2085.	1.3	9
158	Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. <i>Haematologica</i> , 2009, 94, 1618-1622.	3.5	75
159	Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5410-5417.	1.6	687
160	Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. <i>British Journal of Haematology</i> , 2009, 147, 97-101.	2.5	89
161	Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. <i>Internal Medicine Journal</i> , 2009, 39, 304-316.	0.8	44
162	Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure. <i>Journal of Clinical Oncology</i> , 2009, 27, 1788-1793.	1.6	315

#	ARTICLE	IF	CITATIONS
163	Intralesional rituximab for the treatment of localised palatal relapse of follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 303-305.	1.3	2
164	Predicting durable remissions following thalidomide therapy for relapsed myeloma. <i>Leukemia and Lymphoma</i> , 2009, 50, 223-229.	1.3	9
165	How I treat mycosis fungoides and SÅ©zary syndrome. <i>Blood</i> , 2009, 114, 4337-4353.	1.4	144
166	Extracorporeal photopheresis for the treatment of SÅ©zary syndrome using a novel treatment protocol. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 589-595.	1.2	45
167	Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2008, 14, 4500-4510.	7.0	286
168	Clinically Relevant QTc Prolongation Is Not Associated With Current Dose Schedules of LBH589 (panobinostat). <i>Journal of Clinical Oncology</i> , 2008, 26, 332-333.	1.6	41
169	The potential of histone deacetylase inhibitors for the treatment of multiple myeloma. <i>Leukemia and Lymphoma</i> , 2008, 49, 385-387.	1.3	14
170	The development of novel immunotherapeutic approaches in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2008, 49, 652-654.	1.3	3
171	Histone deacetylase inhibitors in lymphoma and solid malignancies. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 413-432.	2.4	89
172	Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. <i>Blood</i> , 2008, 112, 3082-3087.	1.4	160
173	In Vivo Tracking of Dendritic Cells in Patients With Multiple Myeloma. <i>Journal of Immunotherapy</i> , 2008, 31, 166-179.	2.4	38
174	Phase II Trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-Cell Lymphoma (CTCL).. <i>Blood</i> , 2008, 112, 1005-1005.	1.4	42
175	The Frequency, Manifestations and Duration of Prolonged Cytopenias after First Line Fludarabine-Combination Chemotherapy for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma. <i>Blood</i> , 2008, 112, 3176-3176.	1.4	2
176	The Addition of Systemic High-Dose Methotrexate (HD-MTX) to Intrathecal Chemotherapy (IT) for Central Nervous System (CNS) Prophylaxis Substantilly Reduces CNS Recurrence Rates in Patients with at-Risk Aggressive Lymphoma: A Historically Controlled Prospective Study. <i>Blood</i> , 2008, 112, 3596-3596.	1.4	5
177	Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.. <i>Blood</i> , 2008, 112, 958-958.	1.4	32
178	Fludarabine Based Combinations Are Highly Effective as First-Line or Salvage Treatment in Patients with Waldenströ'm Macroglobulinemia. <i>Blood</i> , 2008, 112, 4947-4947.	1.4	1
179	Targeting Lewis Y-Positive Multiple Myeloma and Acute Myeloid Leukemia with Gene-Modified T Cells Demonstrating Memory Phenotype. <i>Blood</i> , 2008, 112, 3900-3900.	1.4	7
180	Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1439-1449.	2.4	38

#	ARTICLE	IF	CITATIONS
181	Denileukin diftitox and vision loss. <i>Leukemia and Lymphoma</i> , 2007, 48, 655-656.	1.3	9
182	Treatment Strategies in Elderly Patients with Multiple Myeloma. <i>Drugs and Aging</i> , 2007, 24, 829-850.	2.7	4
183	An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2007, 48, 46-55.	1.3	50
184	Histone deacetylase inhibitors in cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 659-678.	4.1	193
185	Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome. <i>Haematologica</i> , 2007, 92, 1075-1082.	3.5	36
186	Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison. <i>European Journal of Haematology</i> , 2007, 79, 93-99.	2.2	13
187	The troublesome toxicity of peripheral neuropathy with thalidomide. <i>Leukemia and Lymphoma</i> , 2006, 47, 2276-2279.	1.3	28
188	Immunotherapy of multiple myeloma: the start of a long and tortuous journey. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1769-1785.	2.4	22
189	Preliminary experience of 18F-fluorodeoxyglucose positron emission tomography in Castleman's disease. <i>Leukemia and Lymphoma</i> , 2006, 47, 2664-2666.	1.3	4
190	Methotrexate-induced lymphoproliferative disorder in a patient with SÅžary syndrome. <i>Leukemia and Lymphoma</i> , 2006, 47, 2257-2259.	1.3	7
191	Myeloma, thalidomide and thrombosis. <i>Leukemia and Lymphoma</i> , 2006, 47, 2273-2275.	1.3	5
192	Cefotetanâ€induced lifeâ€threatening haemolysis. <i>Medical Journal of Australia</i> , 2006, 184, 251-251.	1.7	2
193	Current status of new drugs for the treatment of patients with multiple myeloma. <i>Internal Medicine Journal</i> , 2006, 36, 781-789.	0.8	24
194	Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. <i>British Journal of Haematology</i> , 2006, 132, 3-12.	2.5	178
195	In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2006, 56, 155-163.	4.2	55
196	Tumor Lysis Syndrome Early After Treatment with Bortezomib for Multiple Myeloma. <i>Pharmacotherapy</i> , 2006, 26, 1205-1206.	2.6	19
197	Gastric involvement of plasmacytoma associated with t(4:14) and chromosome 13 deletion. <i>Leukemia and Lymphoma</i> , 2006, 47, 1973-1975.	1.3	1
198	Development of Neuropathy in Patients With Myeloma Treated With Thalidomide: Patterns of Occurrence and the Role of Electrophysiologic Monitoring. <i>Journal of Clinical Oncology</i> , 2006, 24, 4507-4514.	1.6	195

#	ARTICLE	IF	CITATIONS
199	The Australian Cancer Anaemia Survey: a snapshot of anaemia in adult patients with cancer. <i>Medical Journal of Australia</i> , 2005, 182, 453-457.	1.7	26
200	A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2005, 11, 5504-5514.	7.0	50
201	Durable remissions are rare following high dose therapy with autologous stem cell transplantation for adults with "paediatric" bone and soft tissue sarcomas. <i>International Seminars in Surgical Oncology</i> , 2005, 2, 12.	1.1	5
202	The adverse prognostic impact of advanced age in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2005, 46, 951-966.	1.3	31
203	A Phase Ib Clinical Trial of PV701, a Milk-Derived Protein Extract, for the Prevention and Treatment of Oral Mucositis in Patients Undergoing High-Dose BEAM Chemotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 512-520.	2.0	15
204	Improved haematopoietic recovery following transplantation with ex vivo -expanded mobilized blood cells*. <i>British Journal of Haematology</i> , 2004, 126, 536-545.	2.5	39
205	Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. <i>American Journal of Hematology</i> , 2004, 77, 72-76.	4.1	104
206	Leukaemic Subtype of Marginal Zone Lymphoma: A Presentation of Three Cases and Literature Review. <i>Leukemia and Lymphoma</i> , 2004, 45, 705-710.	1.3	7
207	Management of the primary cutaneous lymphomas. <i>Australasian Journal of Dermatology</i> , 2003, 44, 227-242.	0.7	20
208	Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. <i>Blood</i> , 2003, 102, 69-77.	1.4	129
209	Cutaneous lymphomas: which pathological classification?. <i>Pathology</i> , 2002, 34, 36-45.	0.6	15
210	RESEARCH REPORT Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: Results of the Australian patients treated on phase II trials. <i>Australasian Journal of Dermatology</i> , 2001, 42, 91-97.	0.7	26
211	Deafness from eighth cranial nerve involvement in a patient with large-cell transformation of mycosis fungoides. <i>European Journal of Haematology</i> , 2000, 64, 340-343.	2.2	26
212	Comparison of COBE _{1/2} Spectra [®] software version 4.7 PBSC and version 6.0 auto PBSC [®] program. <i>Journal of Clinical Apheresis</i> , 1999, 14, 26-30.	1.3	17
213	Fluoro-Gold: An alternative viability stain for multicolor flow cytometric analysis. <i>Cytometry</i> , 1999, 36, 349-354.	1.8	15
214	Prognostic Markers of Disease Activity in Hodgkin's Disease. <i>Leukemia and Lymphoma</i> , 1998, 29, 383-389.	1.3	6
215	Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections. <i>British Journal of Haematology</i> , 1996, 93, 142-145.	2.5	75